Latest TB Alliance Stories
TBA-354 is the first potential tuberculosis drug to advance to Phase 1 trial in six years NEW YORK, Feb.
NEW YORK, Jan.
New multi-year grant continues work to study pressing public health crisis TUCSON, Ariz., Sept.
Brock Will Lead Resource Development, Advocacy, Community Engagement Efforts in Support of Promising Research Pipeline NEW YORK, July 31, 2014 /PRNewswire-USNewswire/
Robertson Will Lead Initiatives to Accelerate Adoption of New TB Drug Regimens NEW YORK, July 31, 2014 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the
Fotouhi to guide organization's discovery-stage research and clinical trials of drug candidates NEW YORK, May 14, 2014 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization
Partnership Supports Newly Announced STAND Trial SEATTLE, April 23, 2014 /PRNewswire-USNewswire/ -- TB Alliance, an international non-profit drug development organization that develops
STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB SEATTLE, April 23, 2014 /PRNewswire-USNewswire/
Multi-year grant brings together non-profits, government, academia and the pharmaceutical industry to study pressing public health challenge TUCSON, Ariz., Feb.
A major trial aiming to cut the rate of tuberculosis (TB) among South Africa's gold miners did not reduce the number of cases or deaths from the disease.
- Withering but not falling off, as a blossom that persists on a twig after flowering.